Genomics plc competitors

J Scott Wolchko are a President/CEO/COO at FATE THERAPEUTICS INC and Board Member at FATE THERAPEUTICS INC. They have worked as Chief Financial Officer at Bocada and VP:Operations/CFO at FATE THERAPEUTICS INC. J studied at University of Virginia and Alpha Omega Alpha Medical Honor Society.

Steven L. Hoerter has served as our Senior Vice President, Commercial since August 2011. From 2010 to 2011, Steven Hoerter was General Manager and Management Center Head at F. Hoffmann-La Roche Ltd. for the Sub-Saharan Africa and Indian Ocean Region, based in Johannesburg, South Africa. From 2005 to 2010, Steven Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech's BioOncology business as Senior Director, Pipeline Development and Commercial Operations. Prior to that he worked at Chiron Corporation and Eli Lilly and Company. During Steven Hoerter's 11-year career at Lilly, he held positions in sales, business development, marketing and business unit management in the US, Europe and Africa. Steven Hoerter has a B.A. in Russian and Political Science from Bucknell University, an M.B.A. from Tilburg University and a M.S. in Management from Purdue University.

Dr. Wei Zhou is Founder, President and CEO of Centrillion. While a student at Stanford, he joined the pioneering genomic technology start-up Affymetrix (now NASDAQ: AFFX) where a generation of future industry leaders and scientists were inspired to change the world for the better through genomics. He continues to be fascinated by the profound and positive impact of genomic technologies in scientific research, health care, agriculture and other fields despite the severe limitations of current genomic technologies and is passionate about making genomic technology accurate and accessible. Prior to founding Centrillion, Dr. Zhou was a partner at the technology law firm Wilson Sonsini Goodrich & Rosati where he advised life sciences, clean tech and digital media companies and venture capital investors. He also served as a senior advisor to the global law firm Covington and Burling. At Affymetrix, he was a vice president of intellectual property and advanced technology until 2008. He was also credited with building Affymetrix’ rapidly growing China business. Dr. Zhou received his PhD from Virginia Tech (John Lee Pratt Fellow), his postdoctoral training from Emory University Medical School and his JD from Stanford University Law School (Associate Editor, Stanford Law Review). He is also a graduate of Harvard Business School’s General Management Program.

Most recently, Dr. Azam was the Head of the Cell & Gene Therapies Unit at Novartis Pharmaceuticals and was a member of the Pharmaceutical Executive Committee. He has an extensive US, Global and International pharmaceutical industry background, with strong experiences in science, clinical development, regulatory and commercial activities. While at Novartis, he lived and worked in the US and Switzerland. Previous roles at Novartis included Head of Global Medical Affairs & HEOR General Medicines, Chief Scientific Officer and Head of US Clinical Development & Medical Affairs and Global Head Regulatory Affairs for the Neurosciences & Ophthalmic Franchise. ​ Prior to Novartis, he was the Chief Executive Officer of Novaccel Therapeutics LLC, a company he founded focusing on accelerating assets in the translational medicine setting. Prior to this he served as Chief Medical Officer at Aspreva Pharmaceutics Inc, a company that focused on orphan and rare autoimmune disease states. Aspreva was acquired by Galenica SA in 2008. Prior to this he worked at Johnson & Johnson in Pharmaceutical Research & Development and in Medical Devices at Johnson & Johnson Ethicon. He started his life sciences career with Warner Lambert-Parke Davis in 1998. Dr. Azam is a member of the Executive Committee of the Alliance for Regenerative Medicine. Dr. Azam is a graduate of the University of Liverpool, United Kingdom, where he completed undergraduate studies in Human Biology & Anatomy. He graduated from the University of Liverpool School of Medicine and attained board certification as an Obstetrician & Gynecologist in the UK.

Andre Ghetti, PhD, is CEO of AnaBios. He was formerly the President of AVIVA Biosciences where he led the growth of the company into drug discovery services and intellectual property commercialization. Prior to joining AVIVA Biosciences Dr. Ghetti was involved in drug discovery programs at Aurora Biosciences first, and later at Vertex Pharmaceuticals. Dr. Ghetti received his Ph.D. in Molecular and Cellular Physiology from the University of Verona (Italy) and completed his postdoctoral training at the California Institute of Technology. Between 1996 and 2001, worked as a staff scientist at the Salk Institute, in La Jolla, California. During the last several years, he has focused on the creation of new tools and strategies to advance biomedical sciences, with special emphasis on enabling the direct study of human biology and pharmacology to accelerate the rate of successful drug discovery and development.

Matthew (Xiaojun) Lei, Ph.D, Bachelor of Medicine, Founder and Chief Executive Officer. Lei is a seasoned executive with broad experience. He has experience in all aspects of company management (Finance, Research, Clinical Development and Manufacturing) and has successfully brought products to markets. He also served as Eastern Regional Account Manager of CVC Microtech with the responsibility for marketing and sales in the eastern region of the US. His academic experience started at Tongji Medical College of Huazhong University of Science and Technology, where Matthew received his medical degree. He received his PhD in Pharmacology from Cornell University, and worked as research associate at Memorial Sloan-Kettering Cancer Center for cancer diagnostics and anti-cancer drug development.

Qasim Rizvi is the Senior Vice President of Operations and Chief Commercial Officer at Kiniksa Pharmaceuticals.

In my 30+ years in the biotech/pharma industry at companies like Elan Pharmaceuticals, Arresto Biosciences and Gilead, I headed the development of mammalian cell lines and manufacturing processes for a number of bio therapeutics for preclinical and clinical programs like Oncology, Multiple Sclerosis and Alzheimer’s disease.In 2012, I founded Celltheon to develop the next generation technology platforms for Biotherapeutics, Bioprocessing and Gene Therapy. Our technology platforms include:- The CELLTHEON SMART™ Platform for recombinant protein expression- The BULLSEYE™ Platform: Bioproduction PD Platform for consistent batch-to-batch CQAs. Proven with 12+ biosimilars in pipeline at various preclinical stages- The PANACEA™ Platform for development of antibodies treatment for infectious diseases- The ACCUFECT™ Platform for efficient ex-vivo bioproduction and in-vivo gene transfer applications- The REPLIVEC™ Platform: Stable off-the-shelf helper-free viral vector expression platform, tissue specific AAV capsids, and tissue specific promotersI also serve on the Board of Keck Graduate Institute’s (KGI) - Amgen Bioprocessing Center Advisory Board (ABCAB), where I also regularly teach classes in cell line development and bioprocessing. I have a number of publications and patents and have won several awards for my contributions in the field of gene expression.More details at www.celltheon.com

Gregory Verdine is a leader in the discovery, development, and commercialization of new drug modalities. A passionate and accomplished inventor of novel approaches and drug classes to engage targets widely believed intractable, Greg coined the phrase “drugging the undruggable” to describe his life mission. LifeMine is the brainchild of Greg, who as a venture partner of WuXi Healthcare Ventures, led the founding team that brought the company from concept to reality. In his role as President, CEO, and CSO of LifeMine, Greg is leading the company through its ramp-up and march toward the clinic. Greg is highly regarded for having moved seamlessly between roles as an academic scientist, biotech entrepreneur, investor, and company executive. As Erving's Professor at Harvard University and Harvard Medical School, he made seminal contributions to understanding mechanisms of DNA repair and epigenetic DNA methylation and he invented a new drug modality called stapled peptides. As an entrepreneur, Greg has founded multiple, public biotech companies including Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, and Aileron, and a private company, Gloucester Pharmaceuticals, that was acquired by Celgene. These companies have succeeded in achieving FDA approval for three marketed drugs. Greg has served on the board of directors of Enanta Pharmaceuticals, Wave Life Sciences, Warp Drive Bio, and FOG Pharmaceuticals. Having led the formation and financing of Wave Life Sciences, Warp Drive Bio, and FOG, Greg took a role in managing these companies as their president, chief executive officer, and chief scientific officer. Greg earned his Ph.D. in chemistry from Columbia University, a B.S. in chemistry from St. Joseph’s University, and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School.